We hypothesise that SGLT2 inhibition activates efferent renal nerves, generating a signal that augments endogenous (hepatic) glucose production, where the stimulus is elaborated to elicit a sympathetic stimulation to sustain glucose production to compensate for the urinary glucose loss and, thus, prevent hypoglycaemia. Here, SLC5A2 is linked to Hypoglycemia.